Fidelity Investments
MAZE

Fidelity Investments’s Maze Therapeutics MAZE Stock Holding History

Fidelity Investments’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.5M Buy
1,056,959
+192,745
+22% +$5.05M ﹤0.01% 1701
2026
Q1 		$25.8M Buy
864,214
+135,609
+19% +$5.98M ﹤0.01% 1691
2025
Q4 		$30.2M Buy
728,605
+72,991
+11% +$2.51M ﹤0.01% 1628
2025
Q3 		$17M Buy
655,614
+101,080
+18% +$1.71M ﹤0.01% 1799
2025
Q2 		$6.8M Sell
554,534
-413,849
-43% -$4.31M ﹤0.01% 2065
2025
Q1 		$10.7M Buy
+968,383
New +$11.7M ﹤0.01% 1885

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Fidelity Investments's MAZE Position: Q2 2026 in Review

Fidelity Investments increased its Maze Therapeutics (MAZE) stake by 22% in Q2 2026, buying an estimated $5.05M and bringing the position to 1,056,959 shares worth $31.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1701.

Fidelity Investments first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Fidelity Investments held 1,056,959 shares of Maze Therapeutics worth $31.5M as of Q2 2026.
  • Fidelity Investments bought 192,745 Maze Therapeutics shares in Q2 2026, an estimated $5.05M.
  • Maze Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1701 holding.
  • Fidelity Investments first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.